VERA - VERA

옵션 체인은 다양한 행사가격과 만기일에 대한 Vera Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Vera Therapeutics에 대한 시장 심리를 평가합니다..

Vera Therapeutics (NASDAQ:VERA) 주식, 옵션 체인

VERA THERAPEUTICS INC

VERAMARK TECHS INC

Vera Therapeutics

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Equities

Macro Economic Events

Macro Notification

Market Summary

News

Sector ETFs

Politics

Treasuries

Economics

Markets

ETFs

COST

INTC

NFLX

NVDA

TSLA

VERA

미국 주식시장은 경제 모멘텀 둔화가 미국 기업들의 실적 전망에 영향을 미칠 수 있다는 투자자들의 우려로 이번 주에 5주 연속 상승세를 마감했다. 미국 경제는 1분기에 연율 1.3% 성장해 이전 추정치 1.6%보다 하향 조정되었다.

이번 주 시장 동향: 월가 5주 연속 상승 마감, 경제 성장 속도 감소, 트럼프의 유죄 평결 등

Southwest Gas Holdings Inc.

Biotech

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Mid Cap

Health Care

Small Cap

Tech

$BTC

AVGO

CVNA

MSTR

SLNO

엔비디아(NASDAQ:NVDA)는 지난 1년간 수익률 순위에서 나스닥 100 지수 1위를 차지하며 눈에 띄는 기술 주식이었다.
이 칩 제조업의 거인은 인공지능(AI) 개발을 위한 칩에 대한 급증하는 수요로, 지난 2023년 5월 말 이후 무려 186%나 급등했다.

엔비디아는 1년 전 대비 186% 상승했지만, 다음의 7개 주식은 이보다 두 배 이상의 수익 기록

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics Inc

Vera Bradley Inc

Veracyte Inc

Veradigm Inc

VERALLIA,COURBEVOIE by VERALLIA, COURBEVOIE

Verallia

Veralto Corp

VERANO HLDGS CORP by Verano Holdings Corp.

Verano Holdings Corp

Verasity

Verastem Inc

<ul>
<li>On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)</li>
<li>U.S. FDA BLA submission for accelerated approval planned for 2H 2025</li>
</ul>
BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN).
"We are grateful for the IgAN community's strong interest in the clinical development of atacicept that helped drive us towards completing full enrollment in the ORIGIN 3 trial with a total of 431 participants. Complete enrollment represents another key milestone on the path to potential approval of the first B cell modulator targeting both BAFF and APRIL for IgAN," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "We anticipate the 36-week primary efficacy endpoint data from the trial this quarter, which supports our planned Biologics License Application for an accelerated approval to the U.S. FDA in the second half of 2025. ORIGIN 3 follows the positive long-term results from the ORIGIN Phase 2b trial that demonstrated sustained and substantial reductions in Gd-IgA1, hematuria and proteinuria, and showed stabilized kidney function through 96 weeks, positioning atacicept as a potential best-in-class IgAN therapy. Pending the submission and thorough FDA review of the BLA, we would look forward to a potential PDUFA date and commercial launch in 2026."
The ORIGIN 3 trial (NCT04716231) is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of atacicept in patients with IgAN who have persistent proteinuria and remain at high risk of disease progression. Participants are randomized 1:1 to at-home self-administered once-weekly subcutaneous injections of atacicept 150 mg or placebo for a 104-week double-blind period, followed by a 52-week open-label extension.
The primary efficacy endpoint is the change in proteinuria as evaluated by urine protein to creatinine ratio (UPCR) through 36 weeks in an interim analysis of at least 200 participants. The key secondary efficacy endpoint is change in kidney function as measured by estimated glomerular filtration rate (eGFR) through 104 weeks in the full study population.

General

Vera Therapeutics Announces Full Enrollment In ORIGIN Phase 3 Trial For Atacicept In IgAN

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight and lowers the price target from $77 to $71.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $71

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Buy and raises the price target from $59 to $61.

Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $61

Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) reported quarterly losses of $(2.75) per share which beat the analyst consensus estimate of $(2.83) by 2.83 percent. This is a 22.22 percent decrease over losses of $(2.25) per share from the same period last year.

Earnings

Vera Therapeutics FY 2024 GAAP EPS $(2.75) Beats $(2.83) Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Joel Beatty initiated coverage on Catalyst Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with an Outperform rating and announced a price target of $28. Catalyst Pharmaceuticals shares closed at $22.62 on Monday. <a href="https://www.benzinga.com/quote/CPRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst John Freeman initiated coverage on Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Strong Buy rating and announced a price target of $135. Expand Energy shares closed at $102.87 on Monday. <a href="https://www.benzinga.com/quote/EXE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst John Kim initiated coverage on Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Market Perform rating and announced a price target of $71. Terreno Realty shares closed at $65.26 on Monday. <a href="https://www.benzinga.com/quote/TRNO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with an Outperform rating and announced a price target of $49. Vera Therapeutics shares closed at $36.54 on Monday. <a href="https://www.benzinga.com/quote/VERA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Oruka Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with an Outperform rating and announced a price target of $20. Oruka Therapeutics shares closed at $13.70 on Monday. <a href="https://www.benzinga.com/quote/ORKA/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock.</a></li>
</ul>
Considering buying EXE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png" alt="" class="wp-image-764898" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Initiation

Pre-Market Outlook

Trading Ideas

CPRX

ORKA

TRNO

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wolfe Research analyst Andy Chen initiates coverage on Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Outperform rating and announces Price Target of $49.

Wolfe Research Initiates Coverage On Vera Therapeutics with Outperform Rating, Announces Price Target of $49

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)</h3>
<ul>
<li>On Jan. 17, HC Wainwright &amp; Co. analyst Joseph Pantginis reiterated Viking Therapeutics with a Buy and maintained a $102 price target.. The company' stock fell around 22% over the past month and has a <a href="https://www.benzinga.com/quote/VKTX">52-week low of $20.83</a>.</li>
<li>RSI Value: 28.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VKTX Price Action: Shares of Viking Therapeutics gained 0.7% to close at $32.87 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">latest VKTX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png" alt="" class="wp-image-744179" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-768x707.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Radnet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Jan. 15, Jefferies analyst Brian Tanquilut maintained RadNet with a Buy rating and lowered the price target from $100 to $80. The company's stock fell around 11% over the past five days and <a href="https://www.benzinga.com/quote/RDNT">has a 52-week low</a> of $35.16.</li>
<li>RSI Value: 25.2</li>
<li>RDNT Price Action: Shares of Radnet gained 0.6% to close at $60.19 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">trend in RDNT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png" alt="" class="wp-image-744183" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-768x704.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Vera Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>)</h3>
<ul>
<li>On Jan. 13, Vera Therapeutics secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera's position in B cell modulation. The company's stock fell around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/VERA">low of $15.46.</a></li>
<li>RSI Value: 27.2</li>
<li>VERA Price Action: Shares of Vera Therapeutics gained 1% to close at $33.70 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">VERA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png" alt="" class="wp-image-744188" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-768x719.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Long Ideas

RDNT

VKTX

Top 3 Health Care Stocks That Could Blast Off This Quarter

Vera Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares are trading lower by 7.3% to $34.31 Monday afternoon. The company announced an <a href="https://www.benzinga.com/pressreleases/25/01/g42940821/vera-therapeutics-acquires-global-rights-to-novel-next-generation-dual-baffapril-inhibitor">exclusive license agreement</a> with Stanford University for VT-109.
What To Know: Vera Therapeutics has secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera&#8217;s position in B cell modulation.
CEO Marshall Fordyce highlighted the company&#8217;s commitment to leveraging its expertise to advance the molecule&#8217;s potential and improve outcomes for patients with severe autoimmune diseases. 
Under the agreement, Vera gains development and marketing rights for VT-109 in exchange for undisclosed upfront and milestone payments.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42953940/tuesdays-producer-inflation-report-could-stoke-market-volatility-as-fed-path-remains-unclear">Tuesday&#8217;s Producer Inflation Report Could Stoke Market Volatility As Fed Path Remains Unclear</a>
<h2 class="wp-block-heading">How To Buy VERA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Vera Therapeutics&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, VERA has a 52-week high of $51.61 and a 52-week low of $14.20.

What's Going On With Vera Therapeutics Stock?

WIIM

Vera Therapeutics shares are trading lower. The company announced an exclusive license agreement with Stanford University for VT-109.

Contracts

Vera Therapeutics Announced An Exclusive License Agreement With Stanford University For Fusion Protein Targeting BAFF And APRIL, Known As VT-109, With Therapeutic Potential Across The Spectrum Of B Cell-mediated Diseases For Undisclosed Upfront And Milestone Payments

Wells Fargo analyst Mohit Bansal initiates coverage on Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight rating and announces Price Target of $70.

Wells Fargo Initiates Coverage On Vera Therapeutics with Overweight Rating, Announces Price Target of $70

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Neutral and raises the price target from $30 to $38.

Wedbush Maintains Neutral on Vera Therapeutics, Raises Price Target to $38

Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.64) by 32.81 percent. This is a 88.89 percent decrease over losses of $(0.45) per share from the same period last year.

Earnings Misses

Vera Therapeutics Q3 EPS $(0.85) Misses $(0.64) Estimate

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight and raises the price target from $72 to $75.

JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $75

Reported Earlier, Vera Therapeutics Prices $300M Public Offering Of 7,142,858 Class A Common Shares At $42/Share

Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.

In connection with the proposed offering, Vera expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering.&nbsp;

Offerings

Vera Therapeutics Plans To Commence Public Offering To Issue And Sell $300M Of Shares Of Its Class A Common Stock

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Buy and raises the price target from $56 to $64.

Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $64

On Saturday, Vera Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41562227/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of-atacicept-in-ig" rel="noreferrer noopener">of long-term follow-up</a>.
These data were presented in a late-breaking oral presentation at the American Society of Nephrology Kidney Week 2024 and published in a&nbsp;manuscript&nbsp;in the&nbsp;Journal of the American Society of Nephrology.
Over 96 weeks, participants treated with atacicept demonstrated a -66% reduction in galactose-deficient IgA1 (Gd-IgA1), resolution of hematuria in 75% of participants, a -52% reduction in proteinuria, and a mean annualized estimated glomerular filtration rate (eGFR) slope of -0.6 mL/min/1.73m2/year.
The cumulative generally favorable safety profile of atacicept remained consistent with that observed during the randomized period, with a 90% completion rate of atacicept treatment.
The company says these data support the potential for atacicept to offer long-term, comprehensive IgAN disease modification and provide further confidence in the ongoing pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN.
The company plans to initiate an ORIGIN Extend study in the fourth quarter of 2024, which will provide ORIGIN participants with extended access to atacicept before its commercial availability.
The ORIGIN 3 trial is on track to announce topline results in the second quarter of 2025, with planned FDA marketing application submission later in the year.
Earlier this year, Vera Therapeutics revealed 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN).&nbsp;
Data from the OLE showed the consistent and sustained reductions of serum galactose-deficient IgA1 (Gd-lgA1), hematuria, and urine protein to creatinine ratio (UPCR), as well as the stability of eGFR over 72 weeks&nbsp;in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36807507/whats-going-on-with-vera-therapeutics-stock-today" rel="noreferrer noopener">participants with IgAN</a>.&nbsp;
Price Action: VERA stock is up 12.2% at $46.12 at last check Monday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41571498/gryphon-digital-restructures-18-million-debt-with-lender-anchorage-grants-it-board-seat" target="_blank" rel="noreferrer noopener">Gryphon Digital Restructures $18 Million Debt With Lender Anchorage, Grants It Board Seat</a></li>
</ul>

Movers

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday.
Shares of PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its <a href="https://www.benzinga.com/quote/PRCT/earnings">FY24 revenue guidance</a>.
PROCEPT BioRobotics shares jumped 25% to $85.87 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Monte Rosa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares jumped 60.5% to $7.85 after the company announced a global license agreement with Novartis to advance VAV1 MGDs. The company will receive a $150 million upfront payment and is eligible for additional milestone payments.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) gained 33.6% to $12.69 after the company showed early trial data for DURAVYU for diabetic macular edema and announced improving vision and anatomy.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares gained 25.5% to $5.89 after the company announced it entered into the sixth amendment to its exclusive distribution agreement with Teoxane.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) gained 19.5% to $6.36.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) rose 15.3% to $44.91. The stock may be moving amid possible volatility as traders evaluate his chance of winning the 2024 presidential election.</li>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) surged 15.3% to $17.66.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) gained 13.8% to $11.09. Ladenburg Thalmann analyst Glenn Mattson initiated coverage on Serve Robotics with a Buy rating and announced a price target of $16.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) rose 12.1% to $46.05 after the company reported 96-week eGFR stabilization on Saturday for its Phase 2b study of IgAN patients with Atacicept.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) gained 10.3% to $19.21.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 10.2% to $7.03.</li>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) gained 9% to $18.03.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) rose 8.3% to $9.45. Canaccord Genuity analyst Brian McNamara maintained Newell Brands with a Buy and raised the price target from $12 to $13.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) gained 7% to $251.00 amid a rise in Bitcoin.</li>
<li>MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) rose 6.3% to $18.14 amid a rise in Bitcoin.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41570746/top-3-real-estate-stocks-that-may-surge-in-q4">Top 3 Real Estate Stocks That May Surge In Q4</a></li>
</ul>

Intraday Update

EYPT

GLUE

IBRX

MARA

MNSO

PRCT

PRTA

RVNC

SERV

WULF

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

Press Releases

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Comments

Vera Therapeutics

Vera Therapeutics (VERA) 옵션

Vera Therapeutics (NASDAQ:VERA) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌